Clinical trials: Metastatic Breast Carcinoma
Metastatic Breast Cancer
Fast-Her: Fasting Effects on Breast Cancer Treatment
We hypothesize that promoting a fasting state will strengthen the anti-cancer effects of PI3K inhibitors in metastatic breast cancer (MBC) treatment.
- Trial name
- NCT07624617
- Testing
- Normal Eating, Prolonged Fasting
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Minnesota
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Breast Cancer Female, Joint Pain
Evaluation of the Efficacy of a Homeopathic Protocol in Patients With Non-metastatic Breast Cancer
Interventional, randomised, prospective, monocentric study
- Trial name
- ARHOMA2 (NCT04408560)
- Testing
- Rhus toxicodendron 9 CH + Ruta graveolens 5 CH (Homeopathic Granules), paracetamol (drug analgesic class1)
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Institut Jean-Godinot
Metastatic Breast Cancer
Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer
To discover if the adding of a coxib increases the efficacy of the Aromasine.
- Trial name
- NCT00525096
- Testing
- Celecoxib, Exemestane
- Volunteers
- 157 people
- Sponsor
- ARCAGY/ GINECO GROUP
Breast Cancer
A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis
This open-label, randomized, parallel arm study will evaluate the effect of capecitabine administered concurrently with WBRT and as maintenance therapy in participants with breast cancer and newly diagnosed brain metastases.
- Trial name
- XERAD (NCT00977379)
- Testing
- WBRT, Capecitabine, Standard of Care
- Where
- 16 sites in France
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
HER2-positive Breast Cancer
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
DEMETHER is a phase II trial exploring the maintenance of trastuzumab and pertuzumab fixed dose combination (FDC) for subcutaneous administration (SC, PHESGO) following trastuzumab deruxtecan (T-DXd) as induction treatment for…
- Trial name
- DEMETHER (NCT06172127)
- Testing
- Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
- Where
- 36 sites in United States, France and 3 more
- Volunteers
- 165 people
- Sponsor
- MedSIR
Advanced or Metastatic Breast Cancer
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
This ia a multicenter, Single-Arm, Open-Label Phase I Clinical Study Evaluating the Safety and Tolerability of Pelareorep Combined with Paclitaxel Injection and the Intracorporal Process of Pelareorep in Chinese Patients with…
- Trial name
- NCT05519059
- Testing
- Pelareorep
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Breast Cancer, HER2 Gene Mutation
Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
- Trial name
- NCT03412383
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Peking Union Medical College
Breast Cancer Metastatic, Breast Cancer Survival
21-gene in Elder Breast Cancer Patients With Lymph Node Metastasis
This study is a single-center, bidirectional cohort study. It aims to include 35 elderly (≥65 years old) Luminal A type breast cancer patients with axillary lymph node metastasis after surgery as the research subjects.
- Trial name
- QiluElderHope (NCT06891651)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Qilu Hospital of Shandong University
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Metastatic Breast Cancer, Locally Advanced Breast Cancer
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive breast cancer and BRCA1 or BRCA2 mutations.
- Conditions
- Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation
- Trial name
- NCT03685331
- Testing
- Palbociclib, Olaparib, Fulvestrant
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Carcinoma, Metastatic Breast Carcinoma
Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer
This study is being done to create a resource of samples and information that can be used to improve our understanding of the development, progression and treatment of recurrent or metastatic breast cancer or male breast cancer.
- Conditions
- Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT06217874
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Mayo Clinic
Breast Cancer
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
RATIONALE: Vaccines made from a person's white blood cells may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways.
- Trial name
- NCT00266110
- Testing
- sargramostim, therapeutic autologous dendritic cells, trastuzumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
RATIONALE: GW572016 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00085020
- Testing
- trastuzumab, lapatinib ditosylate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Non Metastatic Breast Cancer
The Impact of Oncoplastic Breast Surgery on the Oncological Safety and Patient Satisfaction
The aim of this study is to asses the oncological safety of oncoplastic breast surgery, its impact on patient satisfaction and is it worthy for general breast surgeon to learn different oncoplastic techniques.
- Trial name
- NCT02901223
- Testing
- Standard quadrantectomy, oncoplastic breast surgery
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Breast Cancer
Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer
This is a phase II study of the combination of oxaliplatin and trastuzumab as first or second line therapy in patients with stage IV, metastatic breast cancer
- Trial name
- NCT00297596
- Testing
- Trastuzumab, Oxaliplatin
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if capecitabine is more effective than vinorelbine in treating metastatic breast cancer.
- Trial name
- NCT00049660
- Testing
- capecitabine, vinorelbine tartrate
- Where
- 12 sites in Belgium, France and 3 more
- Volunteers
- 47 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Brain Metastases
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.
- Trial name
- NCT02048059
- Testing
- ANG1005
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- Angiochem Inc
Breast Cancer, Breast Neoplasms
Target-specific immunoPET Imaging of Breast Cancer
The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above…
- Conditions
- Breast Cancer, Breast Neoplasms, Breast Cancer Metastatic
- Trial name
- NCT06715826
- Testing
- [18F]F-RESCA-RT4, [18F]F-RESCA-RB14
- Where
- China
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.